摘要
近年来,嵌合抗原受体T细胞(CAR-T)免疫疗法作为肿瘤免疫治疗的新思路,已被证明在血液系统疾病中疗效显著。受此方式启发,学者们开始把研究方向对准肝细胞癌的治疗。目前,CAR-T治疗肝细胞癌的研究已取得了一定成果,但其尚存在实体肿瘤固有屏障、肿瘤微环境、免疫逃逸和特异性肿瘤相关抗原等问题,还需进一步探索。尽管如此,CAR-T免疫疗法将会为肝细胞癌免疫治疗提供更前沿的治疗方式。此外,应用CAR-T与其他方法的联合治疗可能是下一步需要探究的方向。
In recent years,chimeric antigen receptor-modified T-cell(CAR-T)immunotherapy,as a new idea of tumor immunotherapy,has been proved to be effective in hematological diseases.More and more studies have been focusing on this field.At present,some progress have been made in the treatment of hepatocellular carcinoma with CAR-T,but some problems such as solid tumor inherent barrier,tumor microenvironment,immune escape and specific tumor associated antigens still need to be further figure out.Nevertheless,CAR-T immunotherapy will provide a more cutting-edge treatment for hepatocellular carcinoma immunotherapy.In addition,the combination of CAR-T and other methods may also be the direction to be explored in the next step.
作者
付兵
白易
吴昊
张雅敏
Fu Bing;Bai Yi;Wu Hao;Zhang Yamin(The First Central Clinical School,Tianjin Medical University,Tianjin 300192,China;Department of Hepatobiliary Surgery,Tianjin First Center Hospital,Tianjin 300192,China)
出处
《中华肝胆外科杂志》
CAS
CSCD
北大核心
2022年第2期146-150,共5页
Chinese Journal of Hepatobiliary Surgery
基金
天津市自然科学基金(20JCYBJC01310)
天津市科技计划项目(19ZXDBSY00010)
天津市卫生健康科技项目(ZC20064)。
关键词
癌
肝细胞
肿瘤
免疫治疗
嵌合抗原受体T细胞
Carcinoma,hepatocellular
Neoplasms
Immunotherapy
Chimeric antigen receptor-modified T-cell
